<DOC>
	<DOCNO>NCT00242632</DOCNO>
	<brief_summary>This research aim explore effectiveness memantine ( Namenda ) treat post-menopausal woman age 50 65 , risk cognitive decline . Memantine already show offer cognitive benefit patient suffer Alzheimer 's disease , 's potential treating risk cognitive decline without Alzheimer 's disease dementia yet evaluate . It possible memantine may offer neurocognitive benefit population , well . Participants ask take medication six month , complete neuropsychological testing , one blood draw .</brief_summary>
	<brief_title>Treatment With Namenda Women Risk Cognitive Decline</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>: Women age 5065 Willing sign Human Subjects Protection Consent Form Personal family history mood disorder Hypothyroidism Diabetes Family history Alzheimer 's disease Possible probable Alzheimer 's disease dementia History cerebrovascular disease History myocardial infarction within previous year History unstable heart disease Uncontrolled hypertension Less 8 year education English 2nd language Uncorrected vision hear deficit</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>